INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay ...

HealthDay News — Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and obstructive sleep apnea (COBOSA), with providers favoring CPAP and ...

INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in ...

The guidance comes after the agency received 40 reports of unintended pregnancies by women who had been using a weight loss drug. Of particular note is the effect that these drugs may have on the ...

Mumbai: Sales of Mounjaro, Eli Lilly’s blockbuster weight-loss and diabetes drug, have touched Rs 24 crore within three months of its India launch, making it one of the most popular and fastest ...

Ford's new Mustang FX package celebrates the beloved third-generation Fox body with '80s-inspired styling elements and nostalgic interior details for GT Premium models.

Mounjaro manufacturer, Eli Lilly and Company, told UNILAD: "The Mounjaro (tirzepatide) KwikPen is designed to deliver a fixed volume of Mounjaro solution at each dose. "The KwikPen contains sufficient ...

MANILA, Philippines – The Philippine Health Insurance Corporation (PhilHealth) on Friday reminded the public of its rabies benefit package following reported animal bite incidents and rabies ...

TOKYO -- At its next round of tariff negotiations, Japan will present the U.S. with a cooperation package focusing on supply chains for Chinese rare earths and American liquefied natural gas that ...

Today marks the first official agency warning about the possibility of these drugs—specifically Mounjaro—decreasing the effectiveness of oral contraceptives.

Of those, 26 were related to tirzepatide, with one reported as unintentional, and eight reports were for people taking semaglutide. A further nine have been recorded for liraglutide, of which one ...